A meta-analysis revealed that VEGF signaling pathway inhibitors significantly raise the odds of hypertension, cardiac ischemia, arterial thromboembolism, and cardiac dysfunction by 5.3, 2.8, 1.5, and 1.4 times, respectively. Here, VEGFA is linked to hypertensive disorder.